Trellus Health - Clinical research associates GRITT™ resilience-based methodology with significantly reduced healthcare utilisation and opioid use in patients with IBD
Aging populations, poor lifestyles/diets & chronic disease go hand-in-hand.
Moreover, fewer people nowadays are taking responsibility for their own healthcare. Instead becoming increasingly reliant on overburdened organisations like the NHS.
So what’s the solution?
Well in the absence of ‘silver bullet’ cures, then the world needs to shift more towards preventative medicine. Alongside providing patients (where possible) with effective tools to take greater control of their own long term care.
I say this as a Crohn’s sufferer myself. Indeed after exhausting all options (eg Humira), I now treat my IBD through resilience techniques, such as those offered by Trellus Health.
A deep science based telemedicine firm that IPO’d in May’21 raising £28.5m at 40p. In order to commercialise its proprietary, resilience/AI led chronic disease management platform - initially focused on IBD.
Today Trellus Health said a new ‘peer-reviewed' document confirmed that by using its technology.
High risk IBD sufferers (394 sample) not only enjoyed improved resilience (59%), fewer A&E visits (71%) and lower unplanned hospitalisations (94%). But also saw significant decreases in opioid (49%) & corticosteroid (73%) use.
Indicating Trellus' platform has the potential to both transform the quality of life of IBD sufferers, and provide help to other long term chronically sick patients.
Lead author Dr. Laurie Keefer, PhD commenting: "Awareness of the importance of treating the whole person when it comes to chronic disease continues to grow."
"Resilience training works when offered in the setting of quality IBD medical care. When we do not separate physical & mental health, patients can take back control and improve their own outcomes, significantly reducing the need for emergency care &d living their best lives."
CEO Monique Fayad adding: "This will not only lead to improvements in health & quality of life, but also drive significant expense reductions associated with costly unplanned care."
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.